[{"ID":"5378_12-2021_NCT02432196","TOPIC_YEAR":2021,"RESPONSE":"$}}%E2%80%8B%20B%20C%20B%20\n\nBased on the patient's note, the patient is eligible for the clinical trial. The patient has severe mitral regurgitation, which is one of the inclusion criteria for the study. Additionally, the patient has Marfan's syndrome, which is a connective tissue disorder that is not excluded in the study. However, the patient is excluded from the study because of the history of gestational diabetes mellitus, hypertension with pregnancy, and obesity, which are all exclusion criteria.\n\nTherefore, the patient is eligible for the clinical trial, but the Investigator should be aware of the patient's history of gestational diabetes mellitus, hypertension with pregnancy, and obesity and monitor the patient's condition closely during the study.","PROBA":0.9888764253},{"ID":"30612_65-2021_NCT01557465","TOPIC_YEAR":2021,"RESPONSE":"$}}%E2%80%8B%20B%20%20C%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%2","PROBA":0.9983656686},{"ID":"35572_75-2021_NCT02730065","TOPIC_YEAR":2021,"RESPONSE":"$}}%A: eligible%}\n\nThe patient is not eligible for the clinical trial because they do not have cerebral small vessel disease (SVD). The patient has Parkinson's disease, which is not one of the conditions listed in the exclusion criteria, but the patient does not meet the inclusion criteria of having significant SVD, as defined by the presence of multiple lacunes and\/or early confluent or confluent WML on MRI. Additionally, the patient is not a stroke- or dementia-free older adult, which is another inclusion criterion. Therefore, the patient is not eligible for the clinical trial.","PROBA":0.9911059767},{"ID":"33729_71-2021_NCT02774668","TOPIC_YEAR":2021,"RESPONSE":"$}}%E2%80%8B%20eligible%20for%20the%20clinical%20trial.%20She%20meets%20all%20of%20the%20inclusion%20criteria%20and%20none%20of%20the%20exclusion%20criteria.%20The%20patient%E2%80%99s%20BMI%20of%2041.5%20falls%20within%20the%20range%20of%2030-45%20required%20for%20inclusion%20in%20the%20study.%20Additionally%2C%20the%20patient%E2%80%99s%20history%20of%20unsuccessful%20use%20of%20antiobesity%20agents%20and%20appetite%20suppressants%2C%20as%20well%20as%20her%20complaints%20of%20sleep%20apnea%2C%20PCO%20and%20dissatisfaction%20with%20her%20body%20shape%2C%20make%20her%20a%20good%20candidate%20for%20the%20study.%20The%20patient%E2%80%99s%20age%2C%20gender%2C%20and%20teaching%20profession%20are%20not%20exclusionary%20factors%20in%20this%20study.%20Therefore%2C%20the%20patient%20is%20eligible%20for%20the%20clinical%20trial.","PROBA":0.997323461},{"ID":"5443_12-2021_NCT03278574","TOPIC_YEAR":2021,"RESPONSE":"$}}%\n\nBased on the patient's note, the patient has severe mitral valve prolapse with regurgitation, which is a degenerative mitral valve disease. The patient is a good match for the clinical trial because the patient's condition matches the inclusion criteria of the clinical trial. The patient is also not excluded by any of the exclusion criteria. Therefore, the patient is eligible for the clinical trial.\n\nFinal Summary:\nThe patient is eligible for the clinical trial.","PROBA":0.9792385193},{"ID":"35560_75-2021_NCT02657681","TOPIC_YEAR":2021,"RESPONSE":"$}}%E2%80%8B%20B%20%20C%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%2","PROBA":0.9990774105},{"ID":"11642_17-2022_NCT01874132","TOPIC_YEAR":2022,"RESPONSE":"$}}%E2%80%8B%20eligible%20for%20the%20clinical%20trial.%20The%20patient%E2%80%99s%20age%20(67)%20and%20history%20of%20hypertension%20and%20obesity%20meet%20the%20inclusion%20criteria%20for%20the%20study.%20Additionally%2C%20the%20patient%E2%80%99s%20physical%20inactivity%20is%20a%20risk%20factor%20for%20cardiovascular%20disease%2C%20which%20is%20addressed%20by%20the%20study%E2%80%99s%20intervention.%20However%2C%20the%20patient%E2%80%99s%20absence%20of%20severe%20hypertension%20and%20falls%20exclude%20them%20from%20the%20exclusion%20criteria.%20Therefore%2C%20the%20patient%20is%20eligible%20for%20the%20clinical%20trial.","PROBA":0.9940834978},{"ID":"6816_15-2021_NCT02243007","TOPIC_YEAR":2021,"RESPONSE":"$}}%A%]  Based on the patient's note, the patient is eligible for the clinical trial. The patient has a history of coronary artery disease, but it is not considered a serious concomitant systemic disorder incompatible with the study, as it is controlled with medication. The patient also has hypothyroidism, anemia, and chronic kidney disease, but these conditions are not exclusion criteria for the study. The patient has a diagnosis of pancreatic adenocarcinoma, which is the target disease for the clinical trial. Additionally, the patient is scheduled to undergo further evaluation and treatment by an ID specialist as an outpatient, which is consistent with the study's inclusion criteria. Therefore, the patient is eligible for the clinical trial.","PROBA":0.9864894785},{"ID":"5318_12-2021_NCT01708265","TOPIC_YEAR":2021,"RESPONSE":"$}}%\n\nBased on the patient's note, the patient is eligible for the clinical trial. The patient has severe mitral valve regurgitation and preserved left ventricular function, which matches the inclusion criteria of the clinical trial. The patient does not have any of the exclusion criteria, such as pulmonary hypertension, atrial fibrillation, physical inability to undergo surgery, or moderate to severe kidney disease. Therefore, the patient is eligible for the clinical trial.\n\nFinal Summary:\nThe patient is eligible for the Dutch Asymptomatic Mitral Regurgitation Trial.","PROBA":0.9869210414},{"ID":"14106_30-2021_NCT02526719","TOPIC_YEAR":2021,"RESPONSE":"$}}%E2%80%8B%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20C%20B%20","PROBA":0.9999183679},{"ID":"17449_36-2021_NCT04835558","TOPIC_YEAR":2021,"RESPONSE":"$}}%\n\nBased on the patient's note, the patient is eligible for the clinical trial. Here's how I arrived at this conclusion:\n\n1. BMI \u226530 kg\/m2: The patient's BMI is 41.54, which is well above the threshold of 30 kg\/m2, making them eligible for the trial.\n2. Chronic daytime hypercapnia (PaCO2 >45 mm Hg): The patient's PaCO2 level is not explicitly stated in the patient note, but it is mentioned that they have sleep apnea, which is a common symptom of chronic daytime hypercapnia.\n3. Sleep-apnea in the absence of other known causes of hypercapnia: The patient's sleep apnea is not caused by any other known factors, making them eligible for the trial.\n\nTherefore, based on the patient's note, they are eligible for the clinical trial.\n\nFinal Summary: Eligible","PROBA":0.9870739251},{"ID":"6690_15-2021_NCT01252719","TOPIC_YEAR":2021,"RESPONSE":"import re\n\ndef check_eligibility(patient_note, clinical_trial):\n    # Check for inclusion criteria\n    inclusion_patterns = [r\"history of CAD\", r\"recently noted abdominal mass\", r\"fevers\\s+and\\s+bandemia\", r\"pain\\s+radiating\\s+to\\s+the\\s+left\\s+flank\", r\"CT\\s+abdomen\\s+without\\s+contrast\", r\"pancreatic\\s+adenocarcinoma\", r\"spleen\\s+flecture\\s+or\\s+pancreatic\\s+tail\\s+mass\"]\n    for pattern in inclusion_patterns:\n        if not re.search(pattern, patient_note):\n            return False\n    \n    # Check for exclusion criteria\n    exclusion_patterns = [r\"prior\\s+systemic\\s+or\\s+topical\\s+antibacterial\\s+therapy\", r\"known\\s+or\\s+suspected\\s+bacteremia\", r\"severe\\s+sepsis\\s+or\\s+refractory\\s+shock\", r\"infections\\s+associated\\s+with\\s+a\\s+prosthetic\\s+device\", r\"diabetic\\s+foot\\s+infections\", r\"concomitant\\s+infection\\s+at\\s+another\\s+site\", r\"necrotizing\\s+process\\s+gangrene\", r\"infections\\s+known\\s+to\\s+be\\s+caused\\s+by\\s+a\\s+Gram-negative\\s+organism\\s+with\\s+a\\s+vancomycin\\s+MIC\\s+>2\\s+\u03bcg\/mL\", r\"clinically\\s+failing\\s+prior\\s+therapy\\s+with\\s+glycopeptides\"]\n    for pattern in exclusion_patterns:\n        if re.search(pattern, patient_note):\n            return False\n    \n    return True\n\n# Test the function\nprint(check_eligibility(patient_note, clinical_trial))\n\nThe patient is eligible for the clinical trial because none of the exclusion criteria are met. The patient has a history of CAD, recently noted abdominal mass, fevers and bandemia, pain radiating to the left flank, and a CT abdomen without contrast showing a pancreatic adenocarcinoma. However, the patient does not have any of the exclusion criteria, such as prior systemic or topical antibacterial therapy, known or suspected bacteremia, severe sepsis or refractory shock, infections associated with a prosthetic device, diabetic foot infections, concomitant infection at another site, necrotizing process gangrene, or infections known to be caused by a Gram-negative organism with a vancomycin MIC >2 \u03bcg\/mL.","PROBA":0.9971112052},{"ID":"17226_36-2021_NCT03082781","TOPIC_YEAR":2021,"RESPONSE":"$}}%E2%80%8B%20B%20%E2%80%8B%20C%20%E2%80%8B%20B%20%E2%80%8B%20C%20%E2%80%8B%20B%20%E2%80%8B%20C%20%E2%80%8B%20B%20%E2%80%8B%20C%20%E2%80%8B%20B%20%E2%80%8B%20C%20%E2%80%8B%20B%20%E2%80%8B%20C%20%E2%80%8B%20B%20%E2%80%8B%20C%20%E2%80%8B%20B%20%E2%80%8B%20C%20%E2%80%8B%20B%20%E2%80%8B%20C%20%E2%80%8B%20B%20%E2%80%8B%20C%20%E2%80%8B%20B%20%E2%80%8B%20C%20%E2%80%8B%20B%20%E2%80%8B%20C%20%E2%80%8B%20B%20%E2%80%8B%20C%20%E2%80%8B%20B%20%E2%80%8B%20C%20%E2%80%8B%20B%20%E2%80%8B%20C%20%E2%80%8B%20B%20%E2%80%8B%20C%20%E2%80%8B%20B%20%E2%80%8B%20C%20%E2%80%8B%20B%20%E2%80%8B%20C%20%E2%80%8B%20B%20%E2%80%8B%20C%20%E2%80%8B%20B%20%E2%80%8B%20C%20%E2%80%8B%20B%20%E2%80%8B%20C%20%E2%80%8B%20B%20%E2%80%8B%20C%20%E2%80%8B%20B%20%E2%80%8B%20C%20%E2%80%8B%20B%20%E2%80%8B%20C%20%E2%80%8B%20B%20%E2%80%8B%20C%20%E2%80%8B%20B%20%E2%80%8B%20C%20%E2%80%8B%20B%20%E2%80%8B%20C%20%E2%80%8B%20B%20%E2%80%8B%20C%20%E2%80%8B%20B%20%E2%80%8B%20C%20%E2%80%8B%20B%20%E2%80%8B%20C%20%E2%80%8B%20B%20%E2%80%8B%20C%20%E2%80%8B%20B%20%E2%80%8B%20C%20","PROBA":0.9982787871},{"ID":"6894_15-2021_NCT02984501","TOPIC_YEAR":2021,"RESPONSE":"$}}%EOF\n\nBased on the patient's note, the patient is eligible for the clinical trial. The patient has a history of coronary artery disease, mitral valve prolapse, atrial fibrillation, hyperlipemia, hypertension, chronic kidney disease, hypothyroidism, and anemia, all of which are irrelevant to the clinical trial. The patient has a large 9.5 x 7.5 x 6.0-cm heterogeneous left upper abdominal mass consistent with pancreatic adenocarcinoma at the head of pancreas, which meets the inclusion criteria of the clinical trial. The patient has not met any of the exclusion criteria, such as resectable and metastatic disease, previous or concomitant malignant disease, infection, pregnancy or breast-feeding, liver failure, kidney failure, Pa O2 < 65 mmHg, Pa CO2 > 40 mmHg, or mental disability. Therefore, the patient is eligible for the clinical trial.\n\nHere is the final summary:\n\nEligible.","PROBA":0.9852521343},{"ID":"13974_30-2021_NCT00677469","TOPIC_YEAR":2021,"RESPONSE":"$}}%\n\nBased on the patient's note, the patient has Hashimoto's thyroiditis, which is a type of hypothyroidism, not hyperthyroidism. Therefore, the patient is not eligible for the clinical trial. The patient's note also mentions that the patient was started on Levothyroxine, which is a treatment for hypothyroidism.\n\nSo, the final summary is:\n\nB: Excluded - The patient is not eligible for the clinical trial because they have hypothyroidism, not hyperthyroidism.","PROBA":0.9942925507},{"ID":"30893_65-2021_NCT03888664","TOPIC_YEAR":2021,"RESPONSE":"$}}%C%>\n\nBased on the patient's note, the patient does not have Friedreich's Ataxia (FRDA) as their condition is type 1 diabetes. Therefore, the patient is excluded from the clinical trial. The exclusion criteria for the trial specifically state that patients with known sensitivity to \u03b3IFN, previous exposure to recombinant hematopoietin, and ongoing use of desferiprone or other specific FRDA treatments are excluded, and the patient does not meet any of these criteria. Additionally, the patient's age and gender do not match the inclusion criteria for the trial, which specifies that participants must be between the ages of 18 and 40 and must be male or female. Therefore, the patient is excluded from the clinical trial.\n\nFinal Summary:\nThe patient is excluded from the clinical trial because they do not have Friedreich's Ataxia (FRDA) and do not meet the inclusion and exclusion criteria for the trial.","PROBA":0.9903462145},{"ID":"5310_12-2021_NCT01635244","TOPIC_YEAR":2021,"RESPONSE":"$}}%E2%80%8B%20B%20C%20B%20\n\nThe patient is not eligible for the clinical trial because they do not have severe aortic stenosis (AS). The patient has mitral valve prolapse with regurgitation, which is a different condition from AS. Additionally, the patient is excluded from the trial because they have a known severe mitral regurgitation, which is a contraindication for the trial.","PROBA":0.9855405696},{"ID":"17033_36-2021_NCT01492413","TOPIC_YEAR":2021,"RESPONSE":"$}}%E2%80%8B%20A%3A%20eligible%20B%3A%20excluded%20C%3A%20irrelevant%E2%80%8B\">A: eligible<\/option> <option%E2%80%8B%20B%3A%20excluded%20C%3A%20irrelevant%E2%80%8B\">B: excluded<\/option> <option%E2%80%8B%20C%3A%20irrelevant%E2%80%8B\">C: irrelevant<\/option>","PROBA":0.9831279161},{"ID":"6712_15-2021_NCT01442441","TOPIC_YEAR":2021,"RESPONSE":"$}}%E2%80%8B%20A%3A%20eligible%20B:excluded%20C:irrelevant%20\n\nHere is the patient note again:\n70 year-old woman with a history of CAD recently noted abdominal mass who presents with fevers\/rigors and bandemia. Over the last few weeks leading up to admission, she has been experiencing mid-abdominal pain, radiating to the left flank. It lasts throughout the day is not increased by eating though there is associated vomiting and is worsened with coughing. CT abdomen without contrast was then performed on [**4-20**] showing a large 9.5 x 7.5 x 6.0-cm heterogeneous left upper abdominal mass. Patient underwent a EUS with biopsy. The results of the biopsy were consistent with pancreatic adenocarcinoma at the head of pancreas. Splenic flecture\/pancreatic tail mass was also seen on CT, likely diverticular abscess given the patients recent likely history of diverticulitis this was thought to be an infected fluid collection or abscess. She was treated with IV antibiotics (Zosyn, then ceftriaxone and flagyl) and will continue on them until seen by ID as an outpatient. Past Medical History: 1. Coronary artery disease with history of angioplasty in [**State 108**] one year ago 2. Mitral valve prolapse 3. Atrial fibrillation 4. Hyperlipemia 5. Hypertension 6. Chronic kidney disease (SCr 2.1 in [**3-17**]) 7. Hypothyroidism? (TSH 10 in [**3-17**]) 8. Anemia (HCT 30.7 in [**3-17**])\n\nBased on the patient's history and current symptoms, the patient is eligible for the clinical trial. The patient has a history of coronary artery disease, which is not an exclusion criterion. Additionally, the patient's current symptoms of fevers, rigors, and bandemia are consistent with chronic pancreatitis, which is the focus of the clinical trial. The patient's age of 70 is also not an exclusion criterion. Therefore, the patient is eligible for the clinical trial.","PROBA":0.9954336532},{"ID":"33899_71-2021_NCT04197817","TOPIC_YEAR":2021,"RESPONSE":"$}}%E2%80%8B%20B%20C%20B","PROBA":0.9763751924}]
